Request Demo
Last update 24 May 2025
SC-10914
Last update 24 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms S410914, SC 10914, SC10914 |
Target |
Action inhibitors |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (China) |
Login to view timeline
Related
7
Clinical Trials associated with SC-10914NCT04556539
SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial
CTR20201968
食物对SC10914 药代动力学影响的Ⅰ期临床研究
[Translation] Phase I clinical study on the effect of food on the pharmacokinetics of SC10914
NCT04486937
Sc10914 Monotherapy for Metastatic Castration Resistant Prostate Cancer Patients With Germ and / or Somatic BRCA Mutation: a Single Arm, Multicenter Clinical Tria
100 Clinical Results associated with SC-10914
Login to view more data
100 Translational Medicine associated with SC-10914
Login to view more data
100 Patents (Medical) associated with SC-10914
Login to view more data
100 Deals associated with SC-10914
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Endometrioid Carcinoma | Phase 2 | China | 15 Dec 2020 | |
| Ovarian Cancer | Phase 2 | China | 24 Nov 2020 | |
| Ovarian Serous Tumor | Phase 2 | China | 24 Nov 2020 | |
| Ovarian Serous Tumor | Phase 2 | China | 24 Nov 2020 | |
| Locally advanced breast cancer | Phase 2 | China | 12 Aug 2020 | |
| Metastatic breast cancer | Phase 2 | China | 12 Aug 2020 | |
| Neoplasm Metastasis | Phase 2 | China | 12 Aug 2020 | |
| BRCA mutation positive Breast Cancer | Phase 2 | China | 01 Jul 2020 | |
| BRCA mutation positive Breast Cancer | Phase 2 | China | 01 Jul 2020 | |
| Metastatic castration-resistant prostate cancer | Phase 2 | China | 15 Jun 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | HR-positive/HER2-low Solid Tumors BRCA Mutation (germline) | 52 | zuupjakgri(uslmcizcxm) = gsylglmlwj npwjfsivjn (vwslukxyqg ) View more | Positive | 29 May 2020 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free